Pharmaceutical company Celgene acquired Impact


Pharmaceutical company Celgene acquired Impact

When large corporations acquire small biotech startups, it means biomedical industry is growing. United States has examples of large pharmaceutical companies investing in small projects. Celgene, which acquired Impact for 7 billion dollars, is such a company.

John Hood, Executive Director at Impact, said that they were not going to sell the company at the end of last year. In addition, the team didn’t have a general consensus on weather it should be sold or not. But everything was clear after launching production of the drug for patients with myelofibrosis led by Celgene. The company will make the process faster and less risky.

John Hood has become kind of a star in biotechnology, as drug developers usually do not become managers of the business. But he was able to break the pattern: being a Head of Impact, he raised 100 million dollars of investment and managed to sell his company.

Many believe that Celgene overpaid when buying Impact. It is likely Celgene will have to make another expensive deal with other company in the future. The reason is the expiration of the patent for Revlimid, a key product of Celgene. Investors recommended buying Bluebird Bio, a company focused on gene therapy.


Subscribe to the news of M-Health Congress on Facebook and VK!

Innovation news

Selection of health gadgets from CES 2019: part 2

Previous week, M-Health Congress told you about the first top six most impressive health devices...

Global healthcare 2019: development of digital technologies and personalized medicine

Analysts from Deloitte forecast that the global healthcare expenditures may rise to $10.1 trillion by...

Digital medicine as a way to reduce healthcare paperwork

According to Frost&Sullivan, the market of digital healthcare solutions will reach $6 billion by 2021...